Covered recipient · General Payments record
RAJA K SIVAMANI
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$663,153.77
561 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $483,131.01 | 132 |
| Consulting Fee | $101,713.50 | 23 |
| Travel and Lodging | $69,600.46 | 215 |
| Food and Beverage | $8,702.03 | 190 |
| Education | $6.77 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $116,794.70 | 98 |
| UCB, Inc. | $101,505.09 | 140 |
| Lilly USA, LLC | $99,265.83 | 69 |
| Galderma Laboratories, L.P. | $79,699.70 | 47 |
| PFIZER INC. | $73,294.55 | 45 |
| GENZYME CORPORATION | $36,010.14 | 13 |
| Regeneron Healthcare Solutions, Inc. | $31,308.42 | 11 |
| ABBVIE INC. | $25,810.07 | 26 |
| Eli Lilly and Company | $19,844.21 | 18 |
| Almirall LLC | $17,200.00 | 11 |
| LEO Pharma Inc. | $13,337.11 | 12 |
| E.R. Squibb & Sons, L.L.C. | $11,752.99 | 6 |
| Novartis Pharmaceuticals Corporation | $10,016.20 | 27 |
| The Daavlin Distributing Co | $10,000.00 | 1 |
| Janssen Biotech, Inc. | $5,972.98 | 6 |
| Arcutis Biotherapeutics, Inc. | $3,983.69 | 7 |
| Nielsen BioSciences, Inc. | $3,625.00 | 1 |
| SANOFI US SERVICES INC. | $2,335.00 | 1 |
| Insmed, Inc. | $1,114.56 | 7 |
| Amgen Inc. | $97.56 | 5 |
| Organon LLC | $84.91 | 5 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $66.75 | 3 |
| Cipher Pharmaceuticals US LLC | $18.55 | 1 |
| Botanix SB Inc | $15.76 | 1 |
Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RAJA K SIVAMANI
NPI 1811197478 · CMS profile ID 355062
Allopathic & Osteopathic Physicians / Dermatology
SACRAMENTO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1811197478?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RAJA K SIVAMANI, NPI 1811197478, CMS profile ID 355062. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811197478?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). RAJA K SIVAMANI, NPI 1811197478, CMS profile ID 355062. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811197478?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- RAJA K SIVAMANI, NPI 1811197478, CMS profile ID 355062, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1811197478?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
561 matching records · $663,153.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 561.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Incyte Corporation | $4,500.00 | 11/05/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226028945 | CMS |
| Incyte Corporation | $4,500.00 | 11/05/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226028947 | CMS |
| Arcutis Biotherapeutics, Inc. | $11.83 | 11/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252367149 | CMS |
| UCB, Inc. | $589.02 | 11/04/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753999 | CMS |
| Galderma Laboratories, L.P. | $5,600.00 | 11/03/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234704251 | CMS |
| ABBVIE INC. | $17.10 | 10/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204321392 | CMS |
| Incyte Corporation | $1,016.77 | 10/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025724 | CMS |
| Incyte Corporation | $120.49 | 10/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025726 | CMS |
| Incyte Corporation | $2,250.00 | 10/29/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025708 | CMS |
| Incyte Corporation | $889.67 | 10/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226027705 | CMS |
| Incyte Corporation | $4,500.00 | 10/29/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226028135 | CMS |
| ABBVIE INC. | $14.12 | 10/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204321388 | CMS |
| Incyte Corporation | $29.72 | 10/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225983515 | CMS |
| Galderma Laboratories, L.P. | $149.06 | 10/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234704245 | CMS |
| Galderma Laboratories, L.P. | $99.10 | 10/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234704247 | CMS |
| Galderma Laboratories, L.P. | $29.86 | 10/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234704249 | CMS |
| Janssen Biotech, Inc. | $13.70 | 10/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174770614 | CMS |
| LEO Pharma Inc. | $35.57 | 10/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252036590 | CMS |
| ABBVIE INC. | $92.01 | 10/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204321385 | CMS |
| Eli Lilly and Company | $4,400.00 | 10/24/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186884631 | CMS |
| Incyte Corporation | $22.01 | 10/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226024274 | CMS |
| Incyte Corporation | $18.16 | 10/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025696 | CMS |
| Incyte Corporation | $26.99 | 10/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025710 | CMS |
| Incyte Corporation | $18.74 | 10/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025718 | CMS |
| Incyte Corporation | $315.96 | 10/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025720 | CMS |
| Incyte Corporation | $22.98 | 10/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025722 | CMS |
| Incyte Corporation | $43.82 | 10/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025728 | CMS |
| Incyte Corporation | $486.28 | 10/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025730 | CMS |
| Incyte Corporation | $181.19 | 10/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226028137 | CMS |
| SANOFI US SERVICES INC. | $2,335.00 | 10/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233454416 | CMS |
| ABBVIE INC. | $38.11 | 10/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204321375 | CMS |
| ABBVIE INC. | $14.00 | 10/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204321381 | CMS |
| Incyte Corporation | $57.72 | 10/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226025714 | CMS |
| Incyte Corporation | $185.94 | 10/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226027817 | CMS |
| LEO Pharma Inc. | $30.70 | 10/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252036588 | CMS |
| UCB, Inc. | $135.06 | 10/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753993 | CMS |
| UCB, Inc. | $135.06 | 10/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753995 | CMS |
| UCB, Inc. | $135.06 | 10/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753997 | CMS |
| Incyte Corporation | $112.30 | 10/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226027337 | CMS |
| UCB, Inc. | $70.78 | 10/22/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753977 | CMS |
| UCB, Inc. | $70.79 | 10/22/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753979 | CMS |
| UCB, Inc. | $70.79 | 10/22/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753981 | CMS |
| UCB, Inc. | $79.72 | 10/22/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753983 | CMS |
| UCB, Inc. | $79.73 | 10/22/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753985 | CMS |
| UCB, Inc. | $79.73 | 10/22/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753987 | CMS |
| UCB, Inc. | $154.62 | 10/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753989 | CMS |
| UCB, Inc. | $374.25 | 10/22/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753991 | CMS |
| UCB, Inc. | $72.97 | 10/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753969 | CMS |
| UCB, Inc. | $78.28 | 10/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753971 | CMS |
| UCB, Inc. | $388.30 | 10/21/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224753973 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $57,501.69 | 2 |
| PY2025 | Principal investigator | $4,004,892.48 | 257 |
| PY2024 | Recipient | $129,213.85 | 11 |
| PY2024 | Principal investigator | $3,660,171.03 | 220 |
| PY2023 | Recipient | $324.09 | 1 |
| PY2023 | Principal investigator | $1,103,523.70 | 110 |
| PY2022 | Principal investigator | $416,468.20 | 61 |
| PY2021 | Principal investigator | $432,972.16 | 63 |
| PY2020 | Recipient | $2,948.54 | 2 |
| PY2020 | Principal investigator | $317,891.91 | 48 |
| PY2019 | Recipient | $4,530.13 | 23 |
| PY2019 | Principal investigator | $33,261.22 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
259 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202534607 |
| Principal investigator 1 | ABBVIE INC. | $3,537.36 | 12/31/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202534609 |
| Principal investigator 1 | PFIZER INC. | $7,771.29 | 12/31/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228751501 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,641.00 | 12/25/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175176528 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,291.00 | 12/25/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415698 |
| Principal investigator 1 | ABBVIE INC. | $5,149.10 | 12/24/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202532060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,782.00 | 12/22/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175176518 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,792.00 | 12/19/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415749 |
| Principal investigator 1 | PFIZER INC. | $5,981.86 | 12/17/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228736878 |
| Principal investigator 1 | ABBVIE INC. | $1,151.16 | 12/11/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202530250 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,700.00 | 12/09/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) | No dispute reported | 06/30/2026 | 1220802350 |
| Principal investigator 1 | ABBVIE INC. | $11,131.05 | 12/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202528620 |
| Principal investigator 1 | ABBVIE INC. | $36,808.45 | 12/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202528622 |
| Principal investigator 1 | ABBVIE INC. | $8,391.25 | 12/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202528624 |
| Principal investigator 1 | ABBVIE INC. | $14,792.35 | 12/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202528830 |
| Principal investigator 1 | ABBVIE INC. | $15,057.90 | 12/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202528832 |
| Principal investigator 1 | ABBVIE INC. | $454.95 | 12/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202528834 |
| Principal investigator 1 | ABBVIE INC. | $1,678.10 | 12/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202528836 |
| Principal investigator 1 | ABBVIE INC. | $18,974.10 | 12/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202528838 |
| Principal investigator 1 | ABBVIE INC. | $26,833.88 | 12/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202528928 |
| Principal investigator 1 | PFIZER INC. | $5,329.14 | 12/03/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228734628 |
| Principal investigator 1 | PFIZER INC. | $10,938.55 | 11/26/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228739284 |
| Principal investigator 1 | PFIZER INC. | $1,746.23 | 11/25/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228724508 |
| Principal investigator 1 | ABBVIE INC. | $4,735.95 | 11/20/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202524822 |
| Principal investigator 1 | ABBVIE INC. | $11,307.37 | 11/20/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202524824 |
| Principal investigator 1 | ABBVIE INC. | $515.70 | 11/20/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202524832 |
| Principal investigator 1 | ABBVIE INC. | $2,299.04 | 11/20/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202524858 |
| Principal investigator 1 | ABBVIE INC. | $1,054.52 | 11/19/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202524640 |
| Principal investigator 1 | ABBVIE INC. | $2,562.40 | 11/13/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202524115 |
| Principal investigator 1 | ABBVIE INC. | $15,020.82 | 11/13/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202524131 |
| Principal investigator 1 | ABBVIE INC. | $5,007.30 | 11/05/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202522055 |
| Principal investigator 1 | ABBVIE INC. | $5,138.25 | 11/05/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202522057 |
| Principal investigator 1 | ABBVIE INC. | $16,251.30 | 11/05/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202522183 |
| Principal investigator 1 | ABBVIE INC. | $44,453.80 | 11/05/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522185 |
| Principal investigator 1 | PFIZER INC. | $3,093.53 | 11/05/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228729661 |
| Principal investigator 1 | ABBVIE INC. | $13,316.88 | 11/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202520447 |
| Principal investigator 1 | ABBVIE INC. | $37,237.65 | 11/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202520449 |
| Principal investigator 1 | ABBVIE INC. | $12,630.40 | 11/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202520469 |
| Principal investigator 1 | Eli Lilly and Company | $17,182.00 | 11/04/2025 | Non-covered Recipient Entity NORCAL MEDICAL RESEARCH INC | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187885068 |
| Principal investigator 1 | Eli Lilly and Company | $6,560.00 | 11/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187881624 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,710.00 | 11/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415717 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,926.00 | 10/31/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415730 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61.29 | 10/30/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235996589 |
| Principal investigator 1 | PFIZER INC. | $1,746.23 | 10/29/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228741545 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,180.00 | 10/28/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220802338 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,143.62 | 10/28/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190312857 |
| Principal investigator 1 | Eli Lilly and Company | $6,560.00 | 10/27/2025 | Non-covered Recipient Entity NORCAL MEDICAL RESEARCH INC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187886196 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,440.00 | 10/24/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175176536 |
| Principal investigator 1 | PFIZER INC. | $1,584.23 | 10/22/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228741432 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,000.00 | 10/20/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175176553 |
| Principal investigator 1 | Janssen Research & Development, LLC | $313.00 | 10/20/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415634 |
| Principal investigator 1 | ABBVIE INC. | $712.80 | 10/17/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202517425 |
| Principal investigator 1 | ABBVIE INC. | $6,455.85 | 10/15/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202516933 |
| Principal investigator 1 | ABBVIE INC. | $2,469.79 | 10/15/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202516935 |
| Principal investigator 1 | ABBVIE INC. | $1,132.50 | 10/15/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202516937 |
| Principal investigator 1 | ABBVIE INC. | $4,587.60 | 10/15/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202516975 |
| Principal investigator 1 | ABBVIE INC. | $3,339.90 | 10/09/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202515255 |
| Principal investigator 1 | ABBVIE INC. | $20,391.45 | 10/09/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202515437 |
| Principal investigator 1 | ABBVIE INC. | $2,091.90 | 10/09/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202515439 |
| Principal investigator 1 | ABBVIE INC. | $29,267.21 | 10/09/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202515441 |
| Principal investigator 1 | ABBVIE INC. | $4,372.81 | 10/09/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202515443 |
| Principal investigator 1 | ABBVIE INC. | $50,244.10 | 10/09/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202515445 |
| Principal investigator 1 | ABBVIE INC. | $1,470.20 | 10/09/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202515653 |
| Principal investigator 1 | ABBVIE INC. | $9,634.50 | 10/09/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202515657 |
| Principal investigator 1 | Eli Lilly and Company | $3,000.00 | 10/09/2025 | Non-covered Recipient Entity OSMAN DERMATOLOGY | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187889900 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $68,502.10 | 10/08/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220802340 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,404.68 | 10/08/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190312859 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $38,638.50 | 10/07/2025 | Non-covered Recipient Entity Northwestern University | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220796487 |
| Principal investigator 1 | PFIZER INC. | $62.10 | 10/04/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228740696 |
| Principal investigator 1 | ABBVIE INC. | $13,248.00 | 10/01/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | Skin Care | No dispute reported | 06/30/2026 | 1202512950 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,414.00 | 09/29/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175176512 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,840.00 | 09/29/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415660 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,596.00 | 09/29/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415680 |
| Principal investigator 1 | PFIZER INC. | $2,888.33 | 09/26/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228753363 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,201.00 | 09/23/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) | No dispute reported | 06/30/2026 | 1220802348 |
| Principal investigator 1 | Janssen Research & Development, LLC | $698.00 | 09/22/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415621 |
| Principal investigator 1 | PFIZER INC. | $6,218.79 | 09/19/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228768563 |
| Principal investigator 1 | PFIZER INC. | $53,231.16 | 09/12/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228750480 |
| Principal investigator 1 | ABBVIE INC. | $3,160.95 | 09/11/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202510598 |
| Principal investigator 1 | ABBVIE INC. | $515.70 | 09/11/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202510614 |
| Principal investigator 1 | ABBVIE INC. | $17,610.01 | 09/11/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202510616 |
| Principal investigator 1 | ABBVIE INC. | $8,656.40 | 09/11/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202510618 |
| Principal investigator 1 | ABBVIE INC. | $1,404.93 | 09/11/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202510754 |
| Principal investigator 1 | ABBVIE INC. | $3,952.05 | 09/11/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202510756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,535.00 | 09/08/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175176545 |
| Principal investigator 1 | ABBVIE INC. | $4,330.95 | 09/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202508488 |
| Principal investigator 1 | ABBVIE INC. | $45,354.35 | 09/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202508510 |
| Principal investigator 1 | ABBVIE INC. | $3,208.05 | 09/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202508610 |
| Principal investigator 1 | ABBVIE INC. | $29,426.70 | 09/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202508612 |
| Principal investigator 1 | ABBVIE INC. | $17,236.65 | 09/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202507175 |
| Principal investigator 1 | ABBVIE INC. | $1,470.20 | 09/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202507241 |
| Principal investigator 1 | ABBVIE INC. | $26,408.44 | 09/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202508154 |
| Principal investigator 1 | ABBVIE INC. | $25,029.18 | 09/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202508156 |
| Principal investigator 1 | ABBVIE INC. | $7,559.18 | 08/29/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202506529 |
| Recipient | Nielsen BioSciences, Inc. | $40,152.06 | 08/28/2025 | Covered Recipient Physician | CFW--3A | No dispute reported | 06/30/2026 | 1215524931 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,195.00 | 08/25/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) | No dispute reported | 06/30/2026 | 1220802346 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,557.00 | 08/25/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415735 |
| Principal investigator 1 | PFIZER INC. | $7,552.60 | 08/23/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228753355 |
| Principal investigator 1 | ABBVIE INC. | $1,537.65 | 08/19/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202505055 |
| Principal investigator 1 | LEO Pharma AS | $1,000.00 | 08/13/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB | No dispute reported | 06/30/2026 | 1251993671 |
| Recipient | Eli Lilly and Company | $17,349.63 | 08/08/2025 | Covered Recipient Physician | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187872865 |
| Principal investigator 1 | ABBVIE INC. | $3,172.60 | 08/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202503667 |
| Principal investigator 1 | ABBVIE INC. | $12,347.15 | 08/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202503669 |
| Principal investigator 1 | ABBVIE INC. | $8,648.25 | 08/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202503693 |
| Principal investigator 1 | ABBVIE INC. | $2,122.27 | 08/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202503697 |
| Principal investigator 1 | ABBVIE INC. | $10,110.45 | 08/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202502320 |
| Principal investigator 1 | ABBVIE INC. | $87,856.95 | 08/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202502374 |
| Principal investigator 1 | ABBVIE INC. | $8,979.90 | 08/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202502376 |
| Principal investigator 1 | ABBVIE INC. | $7,280.25 | 08/05/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202501126 |
| Principal investigator 1 | ABBVIE INC. | $43,587.15 | 08/05/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202501194 |
| Principal investigator 1 | ABBVIE INC. | $15,089.57 | 08/05/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202501196 |
| Principal investigator 1 | PFIZER INC. | $2,888.33 | 08/05/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228767219 |
| Principal investigator 1 | Amgen Inc. | $12,175.00 | 08/01/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) | No dispute reported | 06/30/2026 | 1246642812 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,557.00 | 08/01/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415705 |
| Principal investigator 1 | Janssen Research & Development, LLC | $42,160.00 | 07/31/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175176503 |
| Principal investigator 1 | PFIZER INC. | $5,593.74 | 07/29/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228763962 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,443.00 | 07/28/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415686 |
| Principal investigator 1 | ABBVIE INC. | $4,023.00 | 07/22/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202499082 |
| Principal investigator 1 | ABBVIE INC. | $2,281.50 | 07/17/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202498696 |
| Principal investigator 1 | PFIZER INC. | $12,739.27 | 07/17/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228771625 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,096.00 | 07/15/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) | No dispute reported | 06/30/2026 | 1220802344 |
| Principal investigator 1 | ABBVIE INC. | $3,060.65 | 07/10/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202497886 |
| Principal investigator 1 | ABBVIE INC. | $513.00 | 07/10/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202497888 |
| Principal investigator 1 | ABBVIE INC. | $6,786.45 | 07/10/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202497892 |
| Principal investigator 1 | ABBVIE INC. | $17,456.15 | 07/10/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202497894 |
| Principal investigator 1 | ABBVIE INC. | $723.60 | 07/10/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202497896 |
| Principal investigator 1 | ABBVIE INC. | $19,487.10 | 07/08/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497182 |
| Principal investigator 1 | ABBVIE INC. | $13,447.95 | 07/08/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202497184 |
| Principal investigator 1 | ABBVIE INC. | $2,728.00 | 07/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202496944 |
| Principal investigator 1 | ABBVIE INC. | $57,050.60 | 07/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202494921 |
| Principal investigator 1 | ABBVIE INC. | $1,678.10 | 07/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202494923 |
| Principal investigator 1 | ABBVIE INC. | $18,445.35 | 07/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202494955 |
| Principal investigator 1 | ABBVIE INC. | $22,675.61 | 07/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202495627 |
| Principal investigator 1 | ABBVIE INC. | $17,533.47 | 07/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202495893 |
| Principal investigator 1 | ABBVIE INC. | $631.20 | 07/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202495895 |
| Principal investigator 1 | PFIZER INC. | $14,500.39 | 07/02/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228784027 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,114.00 | 06/27/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415646 |
| Principal investigator 1 | ABBVIE INC. | $1,657.80 | 06/26/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202493233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,291.00 | 06/26/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415628 |
| Principal investigator 1 | ABBVIE INC. | $1,139.40 | 06/17/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202491789 |
| Principal investigator 1 | ABBVIE INC. | $6,403.65 | 06/17/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202491855 |
| Principal investigator 1 | ABBVIE INC. | $4,097.25 | 06/17/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202491857 |
| Principal investigator 1 | ABBVIE INC. | $4,315.95 | 06/17/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202491859 |
| Principal investigator 1 | ABBVIE INC. | $5,265.00 | 06/16/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202491677 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $217.50 | 06/16/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) | No dispute reported | 06/30/2026 | 1220691767 |
| Principal investigator 1 | ABBVIE INC. | $3,345.30 | 06/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202490029 |
| Principal investigator 1 | ABBVIE INC. | $7,130.70 | 06/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202490031 |
| Principal investigator 1 | ABBVIE INC. | $1,212.30 | 06/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202490067 |
| Principal investigator 1 | ABBVIE INC. | $21,173.55 | 06/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202487737 |
| Principal investigator 1 | ABBVIE INC. | $17,433.75 | 06/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202487761 |
| Principal investigator 1 | ABBVIE INC. | $14,989.80 | 06/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202487765 |
| Principal investigator 1 | ABBVIE INC. | $21,289.93 | 06/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202488679 |
| Principal investigator 1 | ABBVIE INC. | $1,678.10 | 06/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202488697 |
| Principal investigator 1 | ABBVIE INC. | $9,800.24 | 06/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202489349 |
| Principal investigator 1 | ABBVIE INC. | $24,261.30 | 06/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202489351 |
| Principal investigator 1 | ABBVIE INC. | $11,000.00 | 06/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202489427 |
| Principal investigator 1 | PFIZER INC. | $1,821.23 | 05/30/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228765035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,075.00 | 05/26/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415666 |
| Principal investigator 1 | ABBVIE INC. | $1,637.55 | 05/22/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202485849 |
| Principal investigator 1 | PFIZER INC. | $26,663.86 | 05/16/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228774225 |
| Principal investigator 1 | ABBVIE INC. | $5,463.90 | 05/15/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202484937 |
| Principal investigator 1 | ABBVIE INC. | $7,945.75 | 05/15/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202485191 |
| Principal investigator 1 | ABBVIE INC. | $951.15 | 05/15/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202485193 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $217.50 | 05/15/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220691765 |
| Principal investigator 1 | ABBVIE INC. | $5,988.75 | 05/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202483215 |
| Principal investigator 1 | ABBVIE INC. | $11,479.18 | 05/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202483225 |
| Principal investigator 1 | ABBVIE INC. | $12,375.15 | 05/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202483231 |
| Principal investigator 1 | ABBVIE INC. | $69,387.90 | 05/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202483997 |
| Principal investigator 1 | ABBVIE INC. | $67,432.65 | 05/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202483999 |
| Principal investigator 1 | ABBVIE INC. | $2,940.40 | 05/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202481147 |
| Principal investigator 1 | ABBVIE INC. | $26,247.39 | 05/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202482237 |
| Principal investigator 1 | PFIZER INC. | $5,577.52 | 05/03/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228777085 |
| Principal investigator 1 | Eli Lilly and Company | $152,606.00 | 04/29/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187884016 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,949.00 | 04/28/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415670 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,521.00 | 04/25/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415640 |
| Principal investigator 1 | ABBVIE INC. | $904.55 | 04/24/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202478872 |
| Principal investigator 1 | ABBVIE INC. | $515.70 | 04/24/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202478896 |
| Principal investigator 1 | ABBVIE INC. | $922.05 | 04/24/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202478900 |
| Principal investigator 1 | ABBVIE INC. | $4,965.30 | 04/24/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202478960 |
| Principal investigator 1 | ABBVIE INC. | $7,021.91 | 04/24/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202478996 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 04/23/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | SKINMEDICA STUDY | No dispute reported | 06/30/2026 | 1202478618 |
| Principal investigator 1 | ABBVIE INC. | $9,697.76 | 04/17/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE & RESEARCH | A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms | No dispute reported | 06/30/2026 | 1202477381 |
| Principal investigator 1 | ABBVIE INC. | $3,775.95 | 04/14/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202476240 |
| Principal investigator 1 | ABBVIE INC. | $13,860.60 | 04/14/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202476244 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,731.80 | 04/09/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220802336 |
| Principal investigator 1 | PFIZER INC. | $7,161.75 | 04/09/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228796995 |
| Principal investigator 1 | ABBVIE INC. | $1,830.60 | 04/08/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202474876 |
| Principal investigator 1 | ABBVIE INC. | $58,243.90 | 04/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | SKINMEDICA STUDY | No dispute reported | 06/30/2026 | 1202474701 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 04/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | SKINMEDICA STUDY | No dispute reported | 06/30/2026 | 1202474703 |
| Principal investigator 1 | ABBVIE INC. | $24,648.00 | 04/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | SKINMEDICA STUDY | No dispute reported | 06/30/2026 | 1202474708 |
| Principal investigator 1 | ABBVIE INC. | $36,227.10 | 04/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | SKINMEDICA STUDY | No dispute reported | 06/30/2026 | 1202474711 |
| Principal investigator 1 | ABBVIE INC. | $1,844.10 | 04/04/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202474366 |
| Principal investigator 1 | ABBVIE INC. | $12,624.15 | 04/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202469627 |
| Principal investigator 1 | ABBVIE INC. | $28,644.30 | 04/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202469666 |
| Principal investigator 1 | ABBVIE INC. | $16,428.17 | 04/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202469720 |
| Principal investigator 1 | ABBVIE INC. | $20,726.92 | 04/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202469723 |
| Principal investigator 1 | ABBVIE INC. | $3,107.20 | 04/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202470153 |
| Principal investigator 1 | ABBVIE INC. | $21,728.85 | 04/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202470157 |
| Principal investigator 1 | ABBVIE INC. | $3,547.45 | 04/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202470568 |
| Principal investigator 1 | ABBVIE INC. | $37,377.15 | 04/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202470571 |
| Principal investigator 1 | ABBVIE INC. | $6,534.00 | 03/27/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202466803 |
| Principal investigator 1 | ABBVIE INC. | $10,074.46 | 03/27/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202466827 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,774.00 | 03/27/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415711 |
| Principal investigator 1 | PFIZER INC. | $8,745.98 | 03/22/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228794890 |
| Principal investigator 1 | ABBVIE INC. | $2,569.05 | 03/20/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202465155 |
| Principal investigator 1 | ABBVIE INC. | $2,777.05 | 03/20/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202465179 |
| Principal investigator 1 | ABBVIE INC. | $16,463.35 | 03/18/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202464172 |
| Principal investigator 1 | ABBVIE INC. | $65,337.30 | 03/11/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202462353 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $581.10 | 03/11/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220802334 |
| Principal investigator 1 | ABBVIE INC. | $45,456.70 | 03/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460411 |
| Principal investigator 1 | ABBVIE INC. | $30,362.25 | 03/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202461000 |
| Principal investigator 1 | ABBVIE INC. | $37,736.43 | 03/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202461116 |
| Principal investigator 1 | ABBVIE INC. | $20,140.00 | 03/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202461120 |
| Principal investigator 1 | ABBVIE INC. | $27,258.65 | 03/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202461124 |
| Principal investigator 1 | ABBVIE INC. | $4,304.55 | 03/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202461303 |
| Principal investigator 1 | ABBVIE INC. | $12,397.70 | 03/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202457343 |
| Principal investigator 1 | ABBVIE INC. | $824.00 | 03/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202457813 |
| Principal investigator 1 | ABBVIE INC. | $6,484.05 | 03/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202457997 |
| Principal investigator 1 | PFIZER INC. | $4,384.14 | 03/04/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228780351 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,895.00 | 03/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415742 |
| Principal investigator 1 | ABBVIE INC. | $6,923.00 | 02/27/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202454518 |
| Principal investigator 1 | ABBVIE INC. | $5,585.50 | 02/24/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202453649 |
| Principal investigator 1 | ABBVIE INC. | $1,273.55 | 02/20/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202453094 |
| Principal investigator 1 | ABBVIE INC. | $11,760.70 | 02/13/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202451365 |
| Principal investigator 1 | ABBVIE INC. | $10,297.80 | 02/13/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202451417 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $17,962.20 | 02/12/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235996591 |
| Principal investigator 1 | ABBVIE INC. | $4,057.75 | 02/11/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202450531 |
| Principal investigator 1 | PFIZER INC. | $9,244.15 | 02/11/2025 | Non-covered Recipient Entity Integrative Skin Science and Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228761282 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,368.00 | 02/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175415724 |
| Principal investigator 1 | ABBVIE INC. | $12,238.05 | 02/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202448762 |
| Principal investigator 1 | ABBVIE INC. | $2,308.15 | 02/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202448766 |
| Principal investigator 1 | ABBVIE INC. | $24,475.91 | 02/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202448769 |
| Principal investigator 1 | ABBVIE INC. | $5,452.85 | 02/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202448778 |
| Principal investigator 1 | ABBVIE INC. | $6,476.85 | 02/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202448871 |
| Principal investigator 1 | ABBVIE INC. | $10,136.55 | 02/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202448875 |
| Principal investigator 1 | ABBVIE INC. | $87,736.14 | 02/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202448909 |
| Principal investigator 1 | ABBVIE INC. | $31,640.40 | 02/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202449250 |
| Principal investigator 1 | ABBVIE INC. | $19,929.99 | 02/06/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202449254 |
| Principal investigator 1 | ABBVIE INC. | $12,105.85 | 02/05/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202445669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $69.00 | 02/03/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415652 |
| Principal investigator 1 | Amgen Inc. | $122,617.86 | 01/30/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) | No dispute reported | 06/30/2026 | 1246642820 |
| Principal investigator 1 | ABBVIE INC. | $11,167.45 | 01/28/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202441625 |
| Principal investigator 1 | Eli Lilly and Company | $3,377.51 | 01/27/2025 | Non-covered Recipient Entity OSMAN DERMATOLOGY | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187885242 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,414.00 | 01/24/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEAR CH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175415692 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,349.59 | 01/21/2025 | Non-covered Recipient Entity Integrative Skin Science And Research - Location 2 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment | No dispute reported | 06/30/2026 | 1235996585 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,436.31 | 01/21/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs | No dispute reported | 06/30/2026 | 1235996587 |
| Principal investigator 1 | Eli Lilly and Company | $86,380.00 | 01/21/2025 | Non-covered Recipient Entity OSMAN DERMATOLOGY | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187887480 |
| Principal investigator 1 | ABBVIE INC. | $20,390.80 | 01/16/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202439503 |
| Principal investigator 1 | ABBVIE INC. | $696.60 | 01/14/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202438466 |
| Principal investigator 1 | ABBVIE INC. | $688.00 | 01/09/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202437699 |
| Principal investigator 1 | ABBVIE INC. | $188.98 | 01/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202437026 |
| Principal investigator 1 | Amgen Inc. | $25,405.37 | 01/07/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246642825 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,361.50 | 01/07/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220802332 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,232.00 | 01/06/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) | No dispute reported | 06/30/2026 | 1220802342 |
| Principal investigator 1 | ABBVIE INC. | $4,528.80 | 01/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202435198 |
| Principal investigator 1 | ABBVIE INC. | $4,572.10 | 01/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202435306 |
| Principal investigator 1 | ABBVIE INC. | $3,356.20 | 01/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESERCH | M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202435665 |
| Principal investigator 1 | Amgen Inc. | $567,196.84 | 01/02/2025 | Non-covered Recipient Entity INTEGRATIVE SKIN SCIENCE AND RESEARCH | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246642816 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $581.10 | 01/02/2025 | Non-covered Recipient Entity Integrative Skin Science And Research | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220802330 |